Hereditary Angioedema Research

Recent studies on hereditary angioedema (HAE) have focused on improving early diagnosis, treatment strategies, and understanding the genetic basis of the disease. Research from 2019 to 2024 has led to the development of novel therapies, including targeted biologics that inhibit the factors causing angioedema attacks. Clinical trials have shown that these new treatments, including C1-inhibitor replacement therapies and kallikrein inhibitors, significantly reduce the frequency and severity of attacks. The genetic insights gained from recent studies also aid in earlier diagnosis, allowing for more effective long-term management of the condition and better patient outcomes.

    Related Conference of Hereditary Angioedema Research

    January 29-30, 2026

    19th World Drug Delivery Summit

    Paris, France
    February 10-11, 2026

    40th World Congress on Pharmacology and Therapeutics

    Barcelona, Spain
    February 23-24, 2026

    3rd World Congress on Biologics and Biosimilars

    London, UK
    March 23-24, 2026

    36th Annual European Pharma Congress

    London, UK
    March 24-25, 2026

    11th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France

    Hereditary Angioedema Research Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in